1.	Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 30 and under Sponsor: NCI, Other Protocol IDs: ANBL12P1, COG-ANBL12P1, NCI-2012-02211, U10CA098543, NCT01798004
2.	Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 30 and under at diagnosis Sponsor: NCI Protocol IDs: NCI-2009-01064, ANBL0032, U10CA098543, U10CA030969, COG-ANBL0032, COG-P9842, NCT00026312
3.	Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Phase: Phase III Type: Treatment Status: Active Age: 8 and under Sponsor: NCI, Other Protocol IDs: CDR0000069271, COG-ANBL00P3, ANBL00P3, NCT00033293
4.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
5.	Reduced Intensity Transplant Using Extracorporeal Photopheresis Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Pharmaceutical / Industry Protocol IDs: ECP RIT, NCT00179790
6.	Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral ß-glucan for High-Risk Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: 05-075, NCT00911560
7.	Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
8.	A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
9.	Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: H-26652-ATOMIC, NCT01192555
10.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
11.	Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
12.	Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 12 months to 30 years Sponsor: Pharmaceutical / Industry Protocol IDs: NMTRC 004, NCT01483820
13.	Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 21 Sponsor: Pharmaceutical / Industry Protocol IDs: NMTRC 005, NCT01505608
14.	ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 8 and under Sponsor: Pharmaceutical / Industry Protocol IDs: DIV-NB-201, NCT01592045
15.	Study of MLN8237 in Combination With Irinotecan and Temozolomide Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 30 Sponsor: Other Protocol IDs: N2009-03, NCT01601535
16.	Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
17.	Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma Phase: Phase II Type: Treatment Status: Active Age: Over 1 Sponsor: NCI, Other Protocol IDs: 04-148, MSKCC-04148, NCT00107289
18.	Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Phase: Phase II Type: Treatment Status: Active Age: 18 years and under Sponsor: Other Protocol IDs: IRB# 0405652, NCT00202930
19.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
20.	Phase II Study of Protracted Oral Etoposide and Cisplatin During Induction Therapy in Pediatric Patients With Previously Untreated High-Risk Neuroblastoma Undergoing High-Dose Chemotherapy and Stem Cell Rescue Followed by Maintenance Therapy Comprising Isotretinoin Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 18 Sponsor: Other Protocol IDs: BCM-H-20225, 20255, NCT00600132
21.	Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Pharmaceutical / Industry Protocol IDs: V0706, NCT00601003
22.	Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007LS072, UMN-MT2007-07, 0707M11845, UMN-2007LS072, NCT00617929
23.	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7176, NCI-2010-00509, NCT01110135
24.	Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma Phase: Phase II Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 10-015, NCT01114555
25.	MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000680512, COG-ADVL0921, ADVL0921, NCT01154816